Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hemoprinn is a topical gel developed by INNventa Pharm for the management of symptoms associated with hemorrhoids and anal fissures. It functions primarily as an astringent and skin protectant to alleviate itching, burning, and bleeding. The formulation typically contains aluminum potassium sulfate (alum) and tannic acid, which act by precipitating proteins on the surface of mucous membranes, leading to tissue contraction and reduced exudation. Additionally, it often includes soothing agents such as panthenol and chamomile extract (Matricaria chamomilla) to support skin regeneration and reduce local inflammation. Hemoprinn is marketed as a medical device or over-the-counter consumer health product rather than a prescription pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hemoprinn.